Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis - Nkarta (NASDAQ:NKTX)

New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B

Related Keywords

Mylesj Mcdonough ,Paulj Hastings ,Greg Mann ,Roberto Caricchio ,Clinical Program ,Exchange Commission ,Clinical Program Updates ,Nkarta Inc ,Department Of Medicine ,University Of Massachusetts Chan Medical School ,Division Of Rheumatology ,Drug Administration ,Investigational New Drug ,Chief Medical Officer ,Donough Chair ,Massachusetts Chan Medical ,Program Updates ,Program Update ,Rheum Dis Clin North ,Private Securities Litigation Reform Act ,Quarterly Report ,Investor Contact ,